Accumark Labs

CERTIFICATE OF ANALYSIS

Paramount

SAMPLE NAME: DUAL GIP & GLP-1 RECEPTOR AGONIST
SAMPLE CODE: FBNN-Y7N9
RECEIVED DATE: 05/29/2026
PUBLISHED DATE: 08/04/2026




DECLARED IDENTITY	Tirzepatide
MATRIX TYPE:	PEPTIDE
SAMPLE NAME:	DUAL GIP & GLP-1 RECEPTOR AGONIST
SAMPLE SIZE:	100.0 mg
Nº LOT CODE:	DR100N052226

123.99 mg
Total Quantity

99.77%
Total Blend Purity

Sample	Test	Specification	Result	Status
Tirzepatide	IDENTITY	Tirzepatide	Tirzepatide	CONFORMS
Tirzepatide	QUANTITY	MEASURE	123.99 mg	MEASURED
Tirzepatide	PURITY	> 98.0%	99.77%	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:
Anthony Burke PhD
Lab Manager
08/04/2026

RESULTS CERTIFIED BY:
Dr. Levi Fried MD
Lab Director
08/04/2026

ACCUMARKLABS.COM
FBNN-Y7N9
08/04/2026

Accumark Labs

CERTIFICATE OF ANALYSIS

Paramount

SAMPLE NAME: DUAL GIP & GLP-1 RECEPTOR AGONIST
SAMPLE CODE: FBNN-Y7N9
RECEIVED DATE: 05/29/2026
PUBLISHED DATE: 08/04/2026

Sample	Test	Specification	Result	Status
Tirzepatide	Endotoxin (LAL)	≤ 5.0 EU/mL	Pass	CONFORMS
Tirzepatide	Rapid Sterility Screening (PCR)	Not Detected	Pass	CONFORMS

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
08/04/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
08/04/2026